/

Sociétés

Fe

Non vérifié

Ferrer

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueMédecine - DiversSanté

9 communiqués de presse

Voir tous les communiqués de presse

21/10/2025

Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule

Source

Émetteur

1.00

0

17/06/2025

Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)

Source

Émetteur

1.00

0

03/06/2025

A Hundred Experts Urge Strengthening Early Diagnosis of Pulmonary Hypertension in Latin America

Source

Émetteur

1.00

0

28/04/2025

Marché du travail

Biotechnologie

Industrie pharmaceutique

Santé

Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine

Source

Émetteur

1.00

0

31/03/2025

Experts Set International and Multidisciplinary Collaboration As Priorities in Pulmonary Hypertension Management

Source

Émetteur

1.00

0

20/02/2025

Multimédia

Responsabilité sociale d'entreprise

Industrie

Industrie pharmaceutique

Associations/Professionnels

Écologie/Santé environnementale

Transport et expédition de marchandises

Biotechnologie

Logistique

Santé

Ferrer is the Highest-performing Pharmaceutical Company in the World for Social and Environmental Impact According to B Corp

Source

Émetteur

1.00

0

30/01/2025

Ferrer is Recognized for Its Best-in-class Ethics and Compliance Program

Source

Émetteur

1.00

0

20/11/2024

Analyse de marché

Industrie

Science

Médecine - Divers

Cardiologie

Management

Biotechnologie

Santé Publique

Industrie pharmaceutique

Santé

Pulmonary Hypertension Awareness Month: Two European Studies Highlight the Urgency of Patients and Experts to Improve the Diagnosis and Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease

Source

Émetteur

1.00

0

17/09/2024

Multimédia

Industrie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Ferrer Advances Research into Progressive Supranuclear Palsy (PSP) with the Inclusion of the First Participant in a Phase II Clinical Trial

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0